Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated by Analysts at BMO Capital Markets
Stock analysts at BMO Capital Markets started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $50.00 price target on the stock. BMO Capital Markets’ price objective would suggest a potential upside of 320.88% from the […]
